187 related articles for article (PubMed ID: 35635652)
1. Efficacy and safety of regorafenib dose-escalation therapy for Japanese patients with refractory metastatic colorectal cancer (RECC study).
Ishiyama S; Yamada T; Nakamura M; Enomoto M; Sugimoto K; Yokomizo H; Kosugi C; Ohta R; Ishimaru K; Sonoda H; Ishibashi K; Kuramochi H; Yoshida Y; Ichikawa D; Hirata K; Yoshida H; Hashiguchi Y; Ishida H; Koda K; Katsumata K; Sakamoto K
Int J Clin Oncol; 2022 Aug; 27(8):1300-1308. PubMed ID: 35635652
[TBL] [Abstract][Full Text] [Related]
2. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.
Bekaii-Saab TS; Ou FS; Ahn DH; Boland PM; Ciombor KK; Heying EN; Dockter TJ; Jacobs NL; Pasche BC; Cleary JM; Meyers JP; Desnoyers RJ; McCune JS; Pedersen K; Barzi A; Chiorean EG; Sloan J; Lacouture ME; Lenz HJ; Grothey A
Lancet Oncol; 2019 Aug; 20(8):1070-1082. PubMed ID: 31262657
[TBL] [Abstract][Full Text] [Related]
3. Phase II dose titration study of regorafenib in progressive unresectable metastatic colorectal cancer.
Kato T; Kudo T; Kagawa Y; Murata K; Ota H; Noura S; Hasegawa J; Tamagawa H; Ohta K; Ikenaga M; Miyazaki S; Komori T; Uemura M; Nishimura J; Hata T; Matsuda C; Satoh T; Mizushima T; Ohno Y; Yamamoto H; Doki Y; Eguchi H
Sci Rep; 2023 Feb; 13(1):2331. PubMed ID: 36759648
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib in Patients with Antiangiogenic-Naïve and Chemotherapy-Refractory Advanced Colorectal Cancer: Results from a Phase IIb Trial.
Riechelmann RP; Leite LS; Bariani GM; Glasberg J; Rivelli TG; da Fonseca LG; Nebuloni DR; Braghiroli MI; Queiroz MA; Isejima AM; Kappeler C; Kikuchi L; Hoff PM
Oncologist; 2019 Sep; 24(9):1180-1187. PubMed ID: 31175167
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of fruquintinib dose-escalation strategy for elderly patients with refractory metastatic colorectal cancer: A single-arm, multicenter, phase II study.
Tan S; Zhang S; Zhou N; Cai X; Yi C; Gou H
Cancer Med; 2023 Dec; 12(24):22038-22046. PubMed ID: 38063405
[TBL] [Abstract][Full Text] [Related]
6. Association of Hand-Foot Skin Reaction with Regorafenib Efficacy in the Treatment of Metastatic Colorectal Cancer.
Kobayashi K; Kawakami K; Yokokawa T; Aoyama T; Suzuki K; Wakatsuki T; Suenaga M; Sato H; Sugiyama E; Yamaguchi K; Hama T
Oncology; 2019; 96(4):200-206. PubMed ID: 30763946
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
Van Cutsem E; Martinelli E; Cascinu S; Sobrero A; Banzi M; Seitz JF; Barone C; Ychou M; Peeters M; Brenner B; Hofheinz RD; Maiello E; André T; Spallanzani A; Garcia-Carbonero R; Arriaga YE; Verma U; Grothey A; Kappeler C; Miriyala A; Kalmus J; Falcone A; Zaniboni A
Oncologist; 2019 Feb; 24(2):185-192. PubMed ID: 30190299
[TBL] [Abstract][Full Text] [Related]
8. A Phase II Study of Regorafenib With a Lower Starting Dose in Patients With Metastatic Colorectal Cancer: Exposure-Toxicity Analysis of Unbound Regorafenib and Its Active Metabolites (RESET Trial).
Suzuki T; Sukawa Y; Imamura CK; Masuishi T; Satake H; Kumekawa Y; Funakoshi S; Kotaka M; Horie Y; Kawai S; Okuda H; Terazawa T; Kondoh C; Kato K; Yoshimura K; Ishikawa H; Hamamoto Y; Boku N; Takaishi H; Kanai T
Clin Colorectal Cancer; 2020 Mar; 19(1):13-21.e3. PubMed ID: 31732439
[TBL] [Abstract][Full Text] [Related]
9. [Analysis of metastatic colorectal cancer patients treated with regorafenib in real-world practice].
Jiang ZC; Sun YK; Zhang W; Yang L; Cui CX; Wang HY; Zhang HG; Yihebali C; Zhou AP
Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(26):2018-2022. PubMed ID: 32654446
[No Abstract] [Full Text] [Related]
10. Large-Scale, Prospective Observational Study of Regorafenib in Japanese Patients with Metastatic Colorectal Cancer in a Real-World Clinical Setting.
Yamaguchi K; Komatsu Y; Satoh T; Uetake H; Yoshino T; Nishida T; Yamazaki N; Takikawa H; Morimoto T; Chosa M; Sunaya T; Hamada Y; Muro K; Sugihara K
Oncologist; 2019 Jul; 24(7):e450-e457. PubMed ID: 30606885
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Regorafenib With 2/1 Schedule for Patients ≥ 75 Years With Metastatic Colorectal Cancer (mCRC) After Failure of 2 Lines of Chemotherapy.
Petrioli R; Chirra M; Messuti L; Fiaschi AI; Savelli V; Martellucci I; Francini E
Clin Colorectal Cancer; 2018 Dec; 17(4):307-312. PubMed ID: 29548772
[TBL] [Abstract][Full Text] [Related]
12. A phase Ib study of the combination regorafenib with PF-03446962 in patients with refractory metastatic colorectal cancer (REGAL-1 trial).
Clarke JM; Blobe GC; Strickler JH; Uronis HE; Zafar SY; Morse M; Dropkin E; Howard L; O'Neill M; Rushing CN; Niedzwiecki D; Watson H; Bolch E; Arrowood C; Liu Y; Nixon AB; Hurwitz HI
Cancer Chemother Pharmacol; 2019 Oct; 84(4):909-917. PubMed ID: 31444620
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of regorafenib in patients with treatment-refractory metastatic colorectal cancer in Turkey: the single-arm, open-label REGARD study.
Dane F; Ozgurdal K; Yalçın Ş; Benekli M; Aykan NF; Yücel İ; Özkan M; Evrensel T; Sevinç A; Coskun HŞ; Sanli UA; Kara IO; Yumuk PF
BMJ Open; 2020 Mar; 10(3):e027665. PubMed ID: 32220908
[TBL] [Abstract][Full Text] [Related]
14. [Tolerability and efficacy of regorafenib in patients with unresectable metastatic colorectal cancer].
Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1231-6. PubMed ID: 25335705
[TBL] [Abstract][Full Text] [Related]
15. A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors.
Weekes C; Lockhart AC; Lee JJ; Sturm I; Cleton A; Huang F; Lenz HJ
Int J Cancer; 2019 Nov; 145(9):2450-2458. PubMed ID: 30958892
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of the effect of perindopril on hand-foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC.
Melosky BL; Lim HJ; Davies JM; Gill S; Kollmannsberger CK; Ho MY; Vandt SA; Renouf DJ
Cancer Chemother Pharmacol; 2019 Mar; 83(3):411-417. PubMed ID: 30535909
[TBL] [Abstract][Full Text] [Related]
17. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).
Carrato A; Benavides M; Massutí B; Ferreiro-Monteagudo R; García Alfonso P; Falcó E; Reboredo M; Cano T; Gallego J; Viéitez JM; Layos L; Salud A; Polo E; Dotor E; Durán-Ogalla G; Rodriguez-Garrote M; Calvo A; Grande E; Aranda E
BMC Cancer; 2019 Jun; 19(1):533. PubMed ID: 31159765
[TBL] [Abstract][Full Text] [Related]
18. Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.
Hirano G; Makiyama A; Makiyama C; Esaki T; Oda H; Uchino K; Komoda M; Tanaka R; Matsushita Y; Mitsugi K; Shibata Y; Kumagai H; Arita S; Ariyama H; Kusaba H; Akashi K; Baba E
Anticancer Res; 2015 Jan; 35(1):371-7. PubMed ID: 25550574
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib-Induced Hand-Foot Skin Reaction Is More Severe on the Feet Than on the Hands.
Nonomiya Y; Yokokawa T; Kawakami K; Kobayashi K; Aoyama T; Takiguchi T; Sugisaki T; Suzuki K; Suenaga M; Wakatsuki T; Yamaguchi K; Sugimoto Y; Hama T
Oncol Res; 2019 May; 27(5):551-556. PubMed ID: 29914591
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma.
Sun W; Patel A; Normolle D; Patel K; Ohr J; Lee JJ; Bahary N; Chu E; Streeter N; Drummond S
Cancer; 2019 Mar; 125(6):902-909. PubMed ID: 30561756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]